Companies Join Forces to Develop Vectorized Antibody Therapies

VectorY Therapeutics and Annogen have announced a new agreement to work toward developing vectorized antibody therapies for Parkinson’s disease and other neurological conditions. “We are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to…

Biogen and Alectos Team Up to Advance AL01811 for Parkinson’s

Biogen and Alectos Therapeutics have signed an exclusive license and collaboration agreement to further develop and commercialize AL01811, a small molecule therapy, as a potential treatment for Parkinson’s disease. “Through this collaboration with Alectos, we hope to improve the lives of people living with Parkinson’s disease by advancing…

Alector, GSK Partner to Develop 2 Therapies for Dementia

Alector and GlaxoSmithKline (GSK) will collaborate in developing and commercializing two therapies aimed at treating an uncommon type of dementia that can cause problems with behavior and language. Both investigational therapies — AL001 and AL101 — can be used across a range of neurodegenerative disorders, including Parkinson’s,…

e-Therapeutics, C4X Discovery Collaborate to Find New Strategies for Treating Parkinson’s

e-Therapeutics recently entered a collaboration agreement with C4X Discovery to identify new intervention strategies for the treatment of Parkinson’s disease. The collaboration is based on leveraging e-Therapeutics’ Network-Driven Drug Discovery (NDD) platform for drug discovery with C4X Discoveries’ Taxonomy3 technology to identify new cellular mechanisms that are important…